Transcript Document

Thank you for viewing this presentation.
We would like to remind you that this
material is the property of the author.
It is provided to you by the ERS for your
personal use only, as submitted by the
author.
 2012 by the author
European network for study and clinical management
of TB drug resistance.
An integrated approach for controlling MDR-TB spread
in Europe
Daniela M Cirillo
WHO CC for integrated laboratory
strengthening on Tb and other emerging
infections
San Raffaele Scientific Institute, Milan Italy
Overview
 European




consortium with extensive experience in
basic and clinical research relating to MDR-TB, TB
diagnosis, control and epidemiology.
Network of 18 European Countries, 27 beneficiary
Institutions, organized in 8 Work Packages (WP)
dedicated to scientific research and project
management.
Duration 5 yrs (2009-2013).
The main objective of the proposal is to establish an
integrated and synergistic network to address the
challenge of drug resistant TB facing the EU.
Complementary
to
activities
supported
by
International Agencies
Partner Nr. 27:
University of
Medicine and
Dentistry of New
Jersey – USA
Italy: 5
Samara Oblast,
Russian Federation
(subcontractor)
United
Kingdom
Germany: 2
Switzerland: 2
France
Lithuania: 2
Romania: 2
Sweden
Denmark
Croatia
Slovenia
Latvia
Estonia
Norway
Belgium
Finland
Poland
27
PARTNERS
TB PAN-NET Objectives – 1
Main objective:
• Establish an integrated and synergistic network to address the challenge
of drug-resistant TB facing the EU.
Implementation:
• Extensive and focused programme of basic and clinical research to
improve the diagnosis and clinical management of MDR-TB
• Improve our understanding of MDR-TB transmission at molecular level
and host-related risk factors for its development
• Extensive data collection on risk factors and treatment outcomes of
MDR-TB patients from different parts of Europe, to determine risk factors
responsible for MDR-TB development and to define the success of
different treatment regimen on the clinical outcome in relation to the level
of drug-resistance
TB PAN-NET Objectives – 2
Implementation:
• Create a series of field sites across the EU with the capacity for
evaluating new diagnostic systems and novel drug therapies on behalf of
European industry and government.
• Establish a unified and robust QA mechanism for the accurate and rapid
diagnosis of DR and develop appropriate safety standard for European
workers involved in the diagnosis and management of MDR-TB
• Develop a broad training curriculum for the creation of a new generation
of microbiologists, molecular biologists and clinicians expert in DR-TB
management
• Disseminate findings and analyses to the benefit of specialists, general
health care staff, EU governments, non governmental organizations
(NGOs) and health policy makers.
Cooperations in TB PAN-NET
• Molecular epidemiology of MDR-TB in Europe
• SMEs for new diagnostics
• ECDC projects
•Development and dissemination of Training packages
in full agreement with WHO and ECDC guidelines
• Dissemination and information on MDR-TB at
European Level
•Scientific Associations
•
Main achievements up to dates
• Molecular typing platform and data base
• Diagnostics for MDR TB:
– Data on heteroresistance
– New mutations leading to drug resistance
– Therapy monitoring by molecular methods
– Large diagnostics and biomarkers trials
– New approach to EQA for conventional DST
• Prospectic data base on MDR-TB patients and
follow up data